Logo
x

Search

Subscribe Now

Phanes Therapeutics

Phanes Therapeutics’ PT217 Secures the US FDA’s Fast Track Designation for Neuroendocrine Prostate Cancer (NEPC)

Phanes Therapeutics’ PT217 Secures the US FDA’s Fast Track Designation for Neuroendocrine Prostate Cancer (NEPC)

  • December 5, 2024
Phanes Therapeutics Reports the First Patient Dosing with PT886 in P-I/II Study for Pancreatic and Gastric Cancer

Phanes Therapeutics Reports the First Patient Dosing with PT886 in P-I/II Study for Pancreatic and Gastric Cancer

  • September 10, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.